Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Escobar

Showing results (311-320 of 368) with videos related to

Pageof 37
Sort By:
Journal of Clinical Medicine|March 29, 2023
Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection FractionCarlos Escobar, Beatriz Palacios, Victoria Gonzalez, et al.
Journal of Clinical Medicine|July 29, 2025
Integrating New Technologies in Lipidology: A Comprehensive ReviewCarlos Escobar-Cervantes, Jesús Saldaña-García, Ana Torremocha-López, et al.
Expert Review of Cardiovascular Therapy|June 16, 2025
Artificial intelligence: a promising tool for the clinical cardiologistCarlos Escobar, Lorenzo Facila, Rafael Vidal-Pérez, et al.
Current Medical Research and Opinion|March 10, 2023
Identifying the patient with heart failure to be treated with vericiguatCarlos Escobar Cervantes, Alberto Esteban Fernández, Alejandro Recio Mayoral, et al.
Expert Opinion on Pharmacotherapy|March 24, 2023
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalizationAlberto Esteban Fernández, Alejandro Recio Mayoral, Alvaro González Franco, et al.
Hypertension (Dallas, Tex. : 1979)|September 11, 2023
Prognosis of Systolic Pressure 130 to 139 According to Risk. A Prospective Cohort Study Between 1992 and 2019Juan A Divison-Garrote, Julio A Carbayo-Herencia, Marta Simarro-Rueda, et al.
Endocrinologia, Diabetes Y Nutricion|November 19, 2022
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]Juan Pedro-Botet, Vivencio Barrios, Víctor Sánchez-Margalet, et al.
Frontiers in Cardiovascular Medicine|November 24, 2025
Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studiesCarlos Escobar, Pedro Caravaca-Pérez, Jose Maria Fernandez Rodriguez, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|November 5, 2004
Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockersAntonio H Madrid, Irene Marín Marín, Carlos Escobar Cervantes, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 28, 2020
SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic reviewCarlos Escobar, Vivencio Barrios, Juan Cosín, et al.
Pageof 37

Showing results (311-320 of 368) with videos related to

Sort By:
Pageof 37
Journal of Clinical Medicine|March 29, 2023
Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection FractionCarlos Escobar, Beatriz Palacios, Victoria Gonzalez, et al.
Journal of Clinical Medicine|July 29, 2025
Integrating New Technologies in Lipidology: A Comprehensive ReviewCarlos Escobar-Cervantes, Jesús Saldaña-García, Ana Torremocha-López, et al.
Expert Review of Cardiovascular Therapy|June 16, 2025
Artificial intelligence: a promising tool for the clinical cardiologistCarlos Escobar, Lorenzo Facila, Rafael Vidal-Pérez, et al.
Current Medical Research and Opinion|March 10, 2023
Identifying the patient with heart failure to be treated with vericiguatCarlos Escobar Cervantes, Alberto Esteban Fernández, Alejandro Recio Mayoral, et al.
Expert Opinion on Pharmacotherapy|March 24, 2023
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalizationAlberto Esteban Fernández, Alejandro Recio Mayoral, Alvaro González Franco, et al.
Hypertension (Dallas, Tex. : 1979)|September 11, 2023
Prognosis of Systolic Pressure 130 to 139 According to Risk. A Prospective Cohort Study Between 1992 and 2019Juan A Divison-Garrote, Julio A Carbayo-Herencia, Marta Simarro-Rueda, et al.
Endocrinologia, Diabetes Y Nutricion|November 19, 2022
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]Juan Pedro-Botet, Vivencio Barrios, Víctor Sánchez-Margalet, et al.
Frontiers in Cardiovascular Medicine|November 24, 2025
Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studiesCarlos Escobar, Pedro Caravaca-Pérez, Jose Maria Fernandez Rodriguez, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|November 5, 2004
Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockersAntonio H Madrid, Irene Marín Marín, Carlos Escobar Cervantes, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 28, 2020
SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic reviewCarlos Escobar, Vivencio Barrios, Juan Cosín, et al.
Pageof 37